Intensive Interferon Therapy Does Not Increase Virological Response Rates in African Americans with Chronic Hepatitis C
dc.contributor.author | Reddy, Rajender K. | en_US |
dc.contributor.author | Fried, Michael W. | en_US |
dc.contributor.author | Theodore, Dickens | en_US |
dc.contributor.author | Shiffman, Mitchell L. | en_US |
dc.contributor.author | Sterling, Richard K. | en_US |
dc.contributor.author | Bruno, Christine J. | en_US |
dc.contributor.author | Weinstein, Jeffrey | en_US |
dc.contributor.author | Crippin, Jeffrey S. | en_US |
dc.contributor.author | Garcia, Gabriel | en_US |
dc.contributor.author | Wright, Teresa L. | en_US |
dc.contributor.author | Conjeevaram, Hari S. | en_US |
dc.contributor.author | Nolte, Frederick S. | en_US |
dc.date.accessioned | 2006-09-11T14:47:26Z | |
dc.date.available | 2006-09-11T14:47:26Z | |
dc.date.issued | 2003-01 | en_US |
dc.identifier.citation | Theodore, Dickens; Shiffman, Mitchell L.; Sterling, Richard K.; Bruno, Christine J.; Weinstein, Jeffrey; Crippin, Jeffrey S.; Garcia, Gabriel; Wright, Teresa L.; Conjeevaram, Hari; Reddy, Rajender K.; Nolte, Frederick S.; Fried, Michael W.; (2003). "Intensive Interferon Therapy Does Not Increase Virological Response Rates in African Americans with Chronic Hepatitis C." Digestive Diseases and Sciences 48(1): 140-145. <http://hdl.handle.net/2027.42/44431> | en_US |
dc.identifier.issn | 1573-2568 | en_US |
dc.identifier.issn | 0163-2116 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/44431 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12645801&dopt=citation | en_US |
dc.description.abstract | To determine if an intensive regimen of daily, high-dose interferon would improve the initial response rates to therapy for hepatitis C genotype 1 among African American and Caucasian patients, we conducted a retrospective analysis of a treatment trial conducted between October 1995 and June 1997. Patients were randomized to 24 weeks of therapy with interferon −α- 2b at either 5 MU daily or 3 MU three times a week. On the standard interferon regimen (3 MU three times a week) African Americans and Caucasians had similar initial response rates. However, unlike Caucasians, African Americans did not have an increased initial virological response when treated with an intensive, daily dose regimen. Levels of HCV RNA decreased more slowly during the first 12 weeks of therapy among African Americans. Nelson-Aalen cumulative hazard estimates for the different race and dose combinations revealed that Caucasians who received daily interferon were most likely to have an initial response (logrank, P < 0.001). | en_US |
dc.format.extent | 61741 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Gastroenterology | en_US |
dc.subject.other | Race | en_US |
dc.subject.other | Interferon | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Hepatology | en_US |
dc.subject.other | Transplant Surgery | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Hepatitis C | en_US |
dc.subject.other | Therapy | en_US |
dc.subject.other | African American | en_US |
dc.title | Intensive Interferon Therapy Does Not Increase Virological Response Rates in African Americans with Chronic Hepatitis C | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Stanford University, Palo Alto, California | en_US |
dc.contributor.affiliationother | University of California, San Francisco, California | en_US |
dc.contributor.affiliationother | Medical College of Virginia, Richmond, Virginia | en_US |
dc.contributor.affiliationother | Baylor University, Dallas, Texas | en_US |
dc.contributor.affiliationother | Baylor University, Dallas, Texas | en_US |
dc.contributor.affiliationother | Emory University, Atlanta, Georgia | en_US |
dc.contributor.affiliationother | Medical College of Virginia, Richmond, Virginia | en_US |
dc.contributor.affiliationother | University of North Carolina at Chapel Hill, North Carolina | en_US |
dc.contributor.affiliationother | University of Miami, Miami, Florida, USA | en_US |
dc.contributor.affiliationother | Emory University, Atlanta, Georgia | en_US |
dc.contributor.affiliationother | University of North Carolina at Chapel Hill, North Carolina | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 12645801 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/44431/1/10620_2004_Article_458700.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1021750818611 | en_US |
dc.identifier.source | Digestive Diseases and Sciences | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.